A Phase I trial of delta-gD-2 (herpes vaccine)
Latest Information Update: 26 Jul 2019
At a glance
- Drugs Delta gD 2 (Primary)
- Indications Herpes simplex virus infections
- Focus Adverse reactions
Most Recent Events
- 26 Jul 2019 New trial record
- 23 Jul 2019 According to an X-Vax Technology media release, the company raised $56 million in a Series A financing which will be used to advance this trial.